MCID: MCN001
MIFTS: 50

Mucinous Adenocarcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Mucinous Adenocarcinoma

Aliases & Descriptions for Mucinous Adenocarcinoma:

Name: Mucinous Adenocarcinoma 12 14 69
Mucin-Producing Adenocarcinoma 12 69
Pseudomyxoma Peritonei with Unknown Primary Site 12
Mucin-Secreting Adenocarcinoma 12
Mucin-Secreting Carcinoma 12
Adenocarcinoma, Mucinous 42
Mucous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3030
MeSH 42 D002288
SNOMED-CT 64 72495009 900006

Summaries for Mucinous Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which produce mucin.

MalaCards based summary : Mucinous Adenocarcinoma, also known as mucin-producing adenocarcinoma, is related to uterine ligament mucinous adenocarcinoma and large cell neuroendocrine carcinoma. An important gene associated with Mucinous Adenocarcinoma is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Glioma and Development ERBB-family signaling. The drugs Bevacizumab and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include prostate, colon and appendix, and related phenotypes are Decreased viability and cellular

Related Diseases for Mucinous Adenocarcinoma

Diseases related to Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 294)
id Related Disease Score Top Affiliating Genes
1 uterine ligament mucinous adenocarcinoma 33.1 CDX2 KRAS
2 large cell neuroendocrine carcinoma 29.9 CDX2 KRAS KRT20
3 colorectal cancer 28.2 CDKN2A CDX2 EGFR KRAS KRT20 MLH1
4 colon mucinous adenocarcinoma 12.1
5 endometrial mucinous adenocarcinoma 12.1
6 ovarian mucinous adenocarcinoma 12.0
7 mucinous adenocarcinoma of ovary 12.0
8 mucinous adenocarcinoma of the appendix 12.0
9 cervical mucinous adenocarcinoma 11.9
10 villoglandular variant cervical mucinous adenocarcinoma 11.9
11 intestinal variant cervical mucinous adenocarcinoma 11.9
12 ampulla of vater mucinous adenocarcinoma 11.9
13 endocervical type cervical mucinous adenocarcinoma 11.9
14 bile duct mucinous adenocarcinoma 11.9
15 fallopian tube mucinous adenocarcinoma 11.9
16 signet ring cell variant cervical mucinous adenocarcinoma 11.9
17 rectum mucinous adenocarcinoma 11.8
18 appendix adenocarcinoma 11.7
19 pseudomyxoma peritonei 11.3
20 anal colloid adenocarcinoma 11.0
21 adenocarcinoma 10.9
22 cervical adenoma malignum 10.8
23 bladder colloid adenocarcinoma 10.8
24 mucinous stomach adenocarcinoma 10.8
25 prostate colloid adenocarcinoma 10.8
26 prostatitis 10.3
27 cecum adenocarcinoma 10.3 CHST4 MUC2
28 gestational ovarian choriocarcinoma 10.3 MUC1 MUC2
29 choroid epithelioid cell melanoma 10.3 CDX2 MUC2
30 urinary system disease 10.3 MUC1 MUC2
31 ascending colon cancer 10.3 KRT20 MUC2
32 peritoneal benign neoplasm 10.3 CDX2 KRT20
33 dystonia 10.3 CDX2 KRT20
34 anal canal paget's disease 10.3 CDX2 KRT20
35 laryngeal mucoepidermoid carcinoma 10.3 MUC1 MUC2
36 trophoblastic neoplasm 10.2 KRT20 MUC1 MUC2
37 appendix mucinous cystadenocarcinoma 10.2 KRT20 MUC1 MUC2
38 lung clear cell carcinoma 10.2 KRT20 MUC1 MUC2
39 struma ovarii 10.2 KRT20 MUC1 MUC2
40 cervix endometriosis 10.2 CDX2 KRT20 MUC2
41 chromophil adenoma of the kidney 10.2 KRT20 NKX2-1
42 extramedullary plasmacytoma 10.2 CDX2 KRT20
43 vaginal villous adenoma 10.2 CDX2 MUC1 MUC2
44 clitoris cancer 10.2 CDX2 KRT20 MUC1
45 prostate stromal sarcoma 10.2 CDX2 KRT20 MUC2
46 retina lymphoma 10.2 KRAS MUC1 MUC2
47 mesenchymoma 10.2 CDX2 KRT20 MUC1
48 acute retinal necrosis syndrome 10.2 CDX2 KRT20 MUC2
49 spasmodic dysphonia 10.2 KRT20 NKX2-1
50 myotonia congenita 10.2 CDKN2A CDX2 KRT20

Graphical network of the top 20 diseases related to Mucinous Adenocarcinoma:



Diseases related to Mucinous Adenocarcinoma

Symptoms & Phenotypes for Mucinous Adenocarcinoma

GenomeRNAi Phenotypes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.32 EGFR KRAS MUC1
2 Decreased viability GR00106-A-0 9.32 KRAS
3 Decreased viability GR00221-A-1 9.32 EGFR KRAS
4 Decreased viability GR00221-A-2 9.32 KRAS
5 Decreased viability GR00221-A-4 9.32 EGFR
6 Decreased viability GR00301-A 9.32 KRAS
7 Decreased viability GR00381-A-1 9.32 KRAS

MGI Mouse Phenotypes related to Mucinous Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.09 CDKN2A CDX2 CHST4 EGFR KRAS MLH1
2 endocrine/exocrine gland MP:0005379 10.02 ALK CDKN2A CDX2 EGFR KRAS MLH1
3 digestive/alimentary MP:0005381 10.01 CDX2 EGFR KRAS MLH1 MUC2 NKX2-1
4 neoplasm MP:0002006 9.97 ALK CDKN2A CDX2 EGFR KRAS MLH1
5 reproductive system MP:0005389 9.76 NKX2-1 TP53 ALK CDKN2A CDX2 EGFR
6 pigmentation MP:0001186 9.65 ALK CDKN2A EGFR KRAS TP53
7 respiratory system MP:0005388 9.5 ALK CDKN2A EGFR KRAS MLH1 NKX2-1
8 skeleton MP:0005390 9.17 CDKN2A CDX2 EGFR KRAS NKX2-1 TP53

Drugs & Therapeutics for Mucinous Adenocarcinoma

Drugs for Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
2
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
3
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
6
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
7
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
10
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
11
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
12
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
13
Trastuzumab Approved, Investigational Phase 2, Phase 3, Phase 1 180288-69-1 9903
14
Pancrelipase Approved Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
15
Topotecan Approved, Investigational Phase 2, Phase 3, Phase 1 119413-54-6, 123948-87-8 60700
16
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
17
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
18
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
19
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
20
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
21
Goserelin Approved Phase 2, Phase 3 65807-02-5 47725 5311128
22
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 3911 657181
23
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
24
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 14219 4091
25
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
26
Pertuzumab Approved Phase 3,Phase 2 145040-37-5, 380610-27-5 2540
27
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
28
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
30
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
31
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
32
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
33
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3 231277-92-2, 388082-78-8 208908 9941095
34
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
35
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
36
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
37 Alkylating Agents Phase 3,Phase 1,Phase 2
38 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
39 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
40 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
41 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
42 Antidotes Phase 3,Phase 2,Phase 1
43 Antimetabolites Phase 3,Phase 2,Phase 1
44 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
45 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
46 Calcium, Dietary Phase 3,Phase 2,Phase 1
47 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
48 Micronutrients Phase 3,Phase 2,Phase 1,Early Phase 1
49 Mitomycins Phase 3,Phase 1,Phase 2
50 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 230)
id Name Status NCT ID Phase
1 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3
2 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3
3 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
4 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3
5 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
7 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3
8 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3
9 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3
10 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3
11 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
12 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
13 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3
14 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
15 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
16 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3
17 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3
18 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3
19 Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Recruiting NCT02221999 Phase 2, Phase 3
20 Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3
21 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3
22 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3
23 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Recruiting NCT02125344 Phase 3
24 Trial Evaluating Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis Recruiting NCT02179489 Phase 3
25 Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients Recruiting NCT01226394 Phase 3
26 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3
27 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3
28 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3
29 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3
30 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3
31 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3
32 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3
33 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Active, not recruiting NCT01583426 Phase 3
34 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not yet recruiting NCT02839707 Phase 2, Phase 3
35 Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery Terminated NCT00068692 Phase 3
36 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3
37 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3
38 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
39 Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Unknown status NCT01079780 Phase 2
40 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2
41 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2
42 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2
43 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2
44 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2
45 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
46 A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces Completed NCT00162110 Phase 2
47 Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients Completed NCT02575859 Phase 1, Phase 2
48 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2
49 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2
50 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2

Search NIH Clinical Center for Mucinous Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, mucinous

Genetic Tests for Mucinous Adenocarcinoma

Anatomical Context for Mucinous Adenocarcinoma

MalaCards organs/tissues related to Mucinous Adenocarcinoma:

39
Prostate, Colon, Appendix, Ovary, Lung, Pancreas, Cervix

Publications for Mucinous Adenocarcinoma

Articles related to Mucinous Adenocarcinoma:

(show top 50) (show all 542)
id Title Authors Year
1
Metastatic Mucinous Adenocarcinoma and Carcinoid Tumor Arising From a Mature Cystic Teratoma of a Horseshoe Kidney. ( 28083486 )
2017
2
The Importance of Appendectomy in Surgery for Mucinous Adenocarcinoma of the Ovary. ( 28060142 )
2017
3
Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria. ( 27744658 )
2017
4
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. ( 26829311 )
2016
5
Mucinous adenocarcinoma of the bladder: A case report and review of the literature. ( 27703678 )
2016
6
Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma. ( 27342421 )
2016
7
Primary Mucinous Adenocarcinoma of the Urinary Bladder with Signet-Ring Cells: Description of an Uncommon Case and Critical Points in Its Management. ( 28078160 )
2016
8
Primary enteric-type mucinous adenocarcinoma of the renal pelvis masquerading as cystic renal cell carcinoma: A case report and review of the literature. ( 27465836 )
2016
9
Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. ( 26774193 )
2016
10
Palliative Decompression of a Symptomatic Mucinous Adenocarcinoma of the Pancreas. ( 27694871 )
2016
11
Magnetic resonance imaging findings and prognosis of gastric-type mucinous adenocarcinoma (minimal deviation adenocarcinoma or adenoma malignum) of the uterine corpus: Two case reports. ( 27123265 )
2016
12
Long-Term Response After Surgery and Adjuvant Chemoradiation for T4 Mucinous Adenocarcinoma of the Bladder: A Case Report and Review of the Literature. ( 26774348 )
2016
13
Mucinous Adenocarcinoma of the Salivary Gland: A Review of a Rare Tumor. ( 26908552 )
2016
14
Acute Presentation of a Mucinous Adenocarcinoma of the Appendix. ( 27356817 )
2016
15
Primary Pulmonary Mucinous Adenocarcinoma Was Better Visualized on Delayed FDG PET/CT Imaging. ( 27454595 )
2016
16
Contrast-enhanced ultrasound improves accurate identification of appendiceal mucinous adenocarcinoma in an old patient: A case report. ( 27583883 )
2016
17
Pulmonary Kirsten Rat Sarcoma Virus Mutation Positive Mucinous Adenocarcinoma Arising in aA Congenital Pulmonary AirwayA Malformation, Mixed Type 1 and 2. ( 27645976 )
2016
18
Advanced Mucinous Adenocarcinoma Arising from a Mature Cystic Teratoma: A Case Report and Literature Review. ( 27462234 )
2016
19
Conjunctival mucinous adenocarcinoma in an ostrich (Struthio camelus). ( 27362604 )
2016
20
Appendicular mucinous adenocarcinoma associated with pseudomyxoma peritonei, a rare and difficult imaging diagnosis. ( 27239665 )
2016
21
Vulvar mucinous adenocarcinoma with neuroendocrine differentiation: A case report and review of the literature. ( 26861721 )
2016
22
Mucinous adenocarcinoma arising from a residual supratentorial neurenteric cyst and expressing mutated KRAS: a case report. ( 27569299 )
2016
23
HRCT features of surgically resected invasive mucinous adenocarcinoma associated with interstitial pneumonia. ( 27860028 )
2016
24
ALK-rearranged adenocarcinoma with extensive mucin production can mimic mucinous adenocarcinoma: clinicopathological analysis and comprehensive histological comparison with KRAS-mutated mucinous adenocarcinoma. ( 27114375 )
2016
25
mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma. ( 27239184 )
2016
26
Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma. ( 27060927 )
2016
27
Usefulness of (18)F-FDG PET/CT to Detect Metastatic Mucinous Adenocarcinoma Within an Inguinal Hernia. ( 26941865 )
2016
28
Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. ( 27987593 )
2016
29
Intracystic papillary neoplasm with an associated mucinous adenocarcinoma arising in Rokitansky-Aschoff sinus of the gallbladder. ( 27316722 )
2016
30
Squamous esophageal carcinoma and mucinous adenocarcinoma of the colon - an unusual association. ( 27151719 )
2016
31
Salivary mucinous adenocarcinoma of the mandible. ( 27167387 )
2016
32
Clinicopathologic and Prognostic Features in Patients with Peritoneal Metastasis from Mucinous Adenocarcinoma, Adenocarcinoma with Signet Ring Cells, and Adenocarcinoid of the Appendix Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy. ( 26597367 )
2016
33
Pseudomyxoma peritonei with intrathoracic extension: a rare disease with rarer presentation from low-grade mucinous adenocarcinoma of the appendix. ( 26729823 )
2016
34
Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. ( 27626312 )
2016
35
Primary mucinous adenocarcinoma of the vulva: A case report and review of the literature. ( 27073659 )
2016
36
Mucinous adenocarcinoma associated with chronic suppurative hidradenitis: Report of a case and review of the literature. ( 27424105 )
2016
37
A New Hitherto Unreported Histopathologic Manifestation of Mammary Analogue Secretory Carcinoma: "Masked MASC" Associated With Low-grade Mucinous Adenocarcinoma and Low-grade In Situ Carcinoma Components. ( 26808131 )
2016
38
Primary Vaginal Mucinous Adenocarcinoma of Intestinal Type, Associated With Intestinal Metaplasia of Skene Ducts in a Diethylstilbestrol-Exposed Woman. ( 26486744 )
2015
39
Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix. ( 25594636 )
2015
40
Mucinous adenocarcinoma emerging in sigmoid colon neovagina 40A years after its creation: a case report. ( 26159897 )
2015
41
A Simplified Preoperative Assessment Predicts Complete Cytoreduction and Outcomes in Patients with Low-Grade Mucinous Adenocarcinoma of the Appendix. ( 25698402 )
2015
42
C-kit signaling promotes proliferation and invasion of colorectal mucinous adenocarcinoma in a murine model. ( 26356816 )
2015
43
Nonspecific reactivity of polyclonal napsin a antibody in mucinous adenocarcinomas of various sites: a word of caution. ( 25521803 )
2015
44
A rare case of urachal mucinous adenocarcinoma detected by 18F-FDG PET/CT. ( 25608160 )
2015
45
Type C2 radical hysterectomy may improve outcomes of locally advanced mucinous adenocarcinoma of the uterine cervix. ( 26694814 )
2015
46
A case of mucinous adenocarcinoma in the setting of chronic colitis associated with intestinal spirochetosis and intestinal stricture. ( 25634199 )
2015
47
From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report. ( 26555668 )
2015
48
Mucinous Adenocarcinoma of the Male Urethra: A Report of Two Cases. ( 26410973 )
2015
49
The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma. ( 25813151 )
2015
50
A Case of Advanced Mucinous Adenocarcinoma of Bladder in an Adult Patient Treated With Capecitabine-Based Chemotherapy and Review of Literature. ( 25935564 )
2015

Variations for Mucinous Adenocarcinoma

Expression for Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Mucinous Adenocarcinoma.

Pathways for Mucinous Adenocarcinoma

Pathways related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 19)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.79 ALK CDKN2A EGFR KRAS TP53
2
Show member pathways
12.32 EGFR KRAS MUC1 TP53
3 12.32 CDKN2A EGFR KRAS MLH1 TP53
4 12.27 CDKN2A EGFR KRAS TP53
5
Show member pathways
12.09 EGFR KRAS MLH1 TP53
6 11.89 EGFR KRAS MLH1 TP53
7 11.86 EGFR MLH1 TP53
8 11.85 EGFR KRAS TP53
9 11.78 CDKN2A KRAS TP53
10
Show member pathways
11.7 CDKN2A EGFR KRAS TP53
11 11.59 CDKN2A KRAS MLH1 TP53
12 11.52 CDKN2A MLH1 TP53
13 11.45 EGFR KRAS TP53
14 11.3 CDKN2A EGFR KRAS TP53
15 11.29 CDKN2A EGFR TP53
16 11.1 EGFR KRAS TP53
17 10.93 CDKN2A TP53
18
Show member pathways
10.92 CDKN2A TP53
19 10.79 CDKN2A EGFR KRAS TP53

GO Terms for Mucinous Adenocarcinoma

Biological processes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.65 CDKN2A CDX2 EGFR NKX2-1 TP53
2 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.63 KRAS MUC1 MUC2
3 epithelial tube branching involved in lung morphogenesis GO:0060441 9.43 KRAS NKX2-1
4 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.4 MUC1 TP53
5 cerebral cortex cell migration GO:0021795 9.37 EGFR NKX2-1
6 replicative senescence GO:0090399 9.32 CDKN2A TP53
7 positive regulation of cellular senescence GO:2000774 9.16 CDKN2A KRAS
8 Ras protein signal transduction GO:0007265 9.13 CDKN2A KRAS TP53
9 O-glycan processing GO:0016266 8.8 CHST4 MUC1 MUC2

Sources for Mucinous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....